

SYNNESTVEDT & LECHNER LLP

In re application of V. Ramakrishna, et al.
Application No. 10/006,177S&L File P30.631 USA
November 29, 2005
Page 2**Amendments to the Claims**

1. (Currently amended) An isolated oligopeptide or peptide comprising at least one epitopic peptide comprising the amino acid sequence of SEQ ID NO: 4, said oligopeptide or peptide consisting of 9 comprising from 8 to about 30 amino acid residues, wherein said oligopeptide or peptide binds to class I MHC molecules or can be processed to bind to class I MHC molecules.

2. (Previously presented) The oligopeptide of claim 1 wherein said oligopeptide comprises at least two epitopic peptides.

3. (Previously presented) The oligopeptide of claim 1 wherein said oligopeptide comprises at least three epitopic peptides.

4. (Canceled).

4/5. (Currently amended) An isolated oligopeptide or peptide comprising at least one epitopic peptide, said epitopic peptide comprising one amino acid difference from SEQ ID NO: 4, said oligopeptide or peptide consisting of 8 to about 30 amino acid residues, wherein said oligopeptide or peptide binds to class I MHC molecules or can be processed to bind to class I MHC molecules..

SYNNESTVEDT & LECHNER LLP

In re application of V. Ramakrishna, et al.
Application No. 10/006,177S&L File P30,631 USA
November 29, 2005
Page 3

5/6. (Original) The oligopeptide or peptide of claim 5 wherein said one amino acid difference is the result of a conservative amino acid substitution.

6/7. (Previously presented) The oligopeptide or peptide of claim 5 wherein said one amino acid difference is the substitution of one hydrophobic amino acid with another hydrophobic amino acid.

7/8. (Previously presented) The oligopeptide or peptide of claim 5 wherein said amino acid difference is the addition or deletion of one amino acid to or from said epitopic peptide.

Claims 9 to 14 (canceled).

8/15. (Previously presented) A composition comprising an oligopeptide or peptide of claim 1, 2, 3, 5, 6, 7, or 8 present in a pharmaceutically acceptable carrier and in an amount sufficient to elicit production of antibodies or cells that react with said oligopeptide or peptide when said oligopeptide or peptide is administered to an immunologically competent animal.

Claims 16 to 28 (canceled).

9/29. (Previously presented) An immunogen consisting of the amino acid sequence of SEQ ID NO: 4.

SYNNESTVEDT & LECHNER LLP

In re application of V. Ramakrishna, et al.
Application No. 10/006,177

S&L File P30.631 USA
November 29, 2005
Page 4

¹⁰
30. (Previously presented) The oligopeptide of claim 2, said oligopeptide comprising a first epitopic peptide and a second epitopic peptide, wherein said first epitopic peptide comprises the amino acid sequence of SEQ ID NO: 4 and said second epitopic peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-20.